MSN Labs launches Favilow to fight Covid

Hyderabad Hyderabad-based MSN Laboratories Pvt. Ltd. (MSN Labs) has announced the launch of its branded generic, Favilow 800 mg to address the shortage of the antiviral drug, Faripiravir to treat mild and moderate Covid-19 cases. The stronger Favilow 800 mg is priced at Rs 144 per tablet and will be available across pharmacies. The field team of MSN Labs is also helping out with free home delivery in over 170 cities in coordination with local retail chemists for patient convenience.

Dr MSN Reddy, CMD, MSN Group said, "In the light of increasing Covid-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our product Favilow 800 would help support the nation's efforts in overcoming the Covid crisis."

MSN had launched the world's most affordable branded generic of Favipiravir, Favilow, in August last year, in the strengths of 200 and 400 mg. MSN claims the higher strength will improve patient compliance and experience by effectively reducing the number of tablets a patient requires per day. The launch would also address the shortages and issues faced by the patients in procuring the Covid-19 drug.

"MSN is currently manufacturing more than 1 lakh dosage regimen (5 lakh strips of different strengths of FAVILOW) for the treatment of Covid-19 in last 15 days, and are scaling up the manufacturing volumes to 6-8 lakh dosage regimen (30 lakh strips of different strengths of Favilow) by next month," Bharat Reddy, Executive Director, MSN Group said.

MSN successfully developed the active pharmaceutical ingredient (API) and the formulation for Favilow 800 mg in its in-house R&D and manufacturing units.